Healthcare enterprise Centene Corporation (NYSE:CNC) said on Tuesday that its wholly-owned subsidiary, Health Net Federal Services LLC (HNFS), has announced the receipt of the Disease Management Accreditation from URAC effective 1 October 2017 to 1 October 2020.
Founded in 1990, URAC promotes healthcare quality through accreditation, certification and measurement. Its portfolio of accreditation and certification programmes span the healthcare industry, addressing healthcare management, healthcare operations, health plans, pharmacies, telehealth providers, physician practices and more. URAC accreditation is a symbol of excellence for organizations to showcase their validated commitment to quality and accountability.
Since 2011, HNFS has continuously held URAC's Disease Management Accreditation.
HNFS' Disease Management Education Programme serves TRICARE North Prime beneficiaries, identified by the Defense Health Agency, for enrollment in healthcare management programmes targeting six conditions: anxiety, asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure, depression and diabetes.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies